Figure 1. Temozolomide (TMZ) activation and methylation of multiple cellular targets

From

Dual Epigenetic Impacts of Temozolomide on the Sensitivity of ER-positive and ER-negative Breast Cancer and Glioma Cells

Viacheslav S, Jorge S., Perez C., Prajapati J., Diaz A.J., Wang T.

American Journal of Medicine Studies. 2026, 11(1), 8-15 doi:10.12691/ajms-11-1-2